Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany

Table 4

Chi-square test for variables with potential predictive value regarding the likelihood of HER2-testing. Included in the analysis are only patients not participating in clinical trials (2010 + 2011: ; 2012 + 2013: ). AEG = adenocarcinoma of the esophagogastric junction.

Variable	2010 + 2011; value	2012 + 2013; value
Karnofsky performance status ≤80 versus >80	<0.001	0.391
Age ≤ 65	<0.001	0.039
Number of metastases: none/singular versus multiple	<0.001	0.008
Treated concomitant disease: yes versus none	0.025	0.003
Objective of treatment: “resectability of the primary tumor”: yes versus no	0.023	0.275
Objective of treatment: “prevention of progression”: yes versus no	0.003	0.006

Note. The included patients differ according to the valid answers.